In the latest article about the apparent end of the semaglutide shortage, the Advisory Board (which...
WSJ, GLP-1s (and APC)
The Wall Street Journal is looking past the FDA’s official ending of the GLP-1 shortages and into the future of compounding them. Its story, “Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren’t Happy” looks at the ways those telehealth companies plan to keep offering compounded GLP-1s — and whether that will pass muster. (Of course the Journal turned to APC for some perspective.)
